Decreased cabotegravir plasma concentrations, leading to loss of efficacy.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Integrase Inhibitor · Antiretroviral
Cabotegravir blocks the catalytic activity of the HIV-encoded integrase of HIV-1 and HIV-2, preventing the integration of viral DNA into the host chromosome. It interferes with essential divalent cations in the enzyme’s catalytic core.
Decreased cabotegravir plasma concentrations, leading to loss of efficacy.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Decreased cabotegravir plasma concentrations, leading to loss of efficacy.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Decreased cabotegravir plasma concentrations, leading to loss of efficacy.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: others
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
3 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team